Enlitic Secures AU$15 Million Funding to Accelerate AI Healthcare Expansion and Strengthen Balance Sheet
Enlitic, Inc. (ASX: ENL) has secured binding commitments for a conditional capital raising of approximately AU$15 million, alongside plans for a Security Purchase Plan targeting up to AU$1 million. The funding is expected to strengthen the company's financial position, support commercial expansion, and provide sufficient capital to operate through to anticipated cashflow break-even. A proposed conversion of outstanding convertible notes into equity is also expected to eliminate debt and simplify the capital structure, while a planned 10-for-1 share consolidation aims to streamline the company's share base. The proceeds will primarily be directed toward expanding the commercial rollout of Enlitic's AI-powered medical imaging software, enhancing sales and marketing, product development, regulatory compliance, customer support, and working capital. Subject to shareholder approvals, the initiatives are expected to leave the company with approximately AU$18 million in pro forma cash, positioning Enlitic to pursue growth opportunities across the global healthcare imaging market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Enlitic Secures AU$15 Million Funding to Accelerate AI Healthcare Expansion and Strengthen Balance Sheet
Enlitic, Inc. (ASX: ENL) has secured binding commitments for a conditional capital raising of approximately AU$15 million, alongside plans for a Security Purchase Plan targeting up to AU$1 million. The funding is expected to strengthen the company's financial position, support commercial expansion, and provide sufficient capital to operate through to anticipated cashflow break-even. A proposed conversion of outstanding convertible notes into equity is also expected to eliminate debt and simplify the capital structure, while a planned 10-for-1 share consolidation aims to streamline the company's share base. The proceeds will primarily be directed toward expanding the commercial rollout of Enlitic's AI-powered medical imaging software, enhancing sales and marketing, product development, regulatory compliance, customer support, and working capital. Subject to shareholder approvals, the initiatives are expected to leave the company with approximately AU$18 million in pro forma cash, positioning Enlitic to pursue growth opportunities across the global healthcare imaging market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au